{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:11:22Z","timestamp":1788495082725,"version":"build-2803163510"},"reference-count":55,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T00:00:00Z","timestamp":1341878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold>Defining the tolerability and safety profile of recently marketed antiepileptic drugs, such as lacosamide (LCM), is a prerequisite for their optimal utilization in clinical practice. We aimed to identify any adverse event (AE) associated with LCM treatment by conducting a systematic review and meta\u2010analysis of all available randomized controlled trials (RCTs). We also evaluated the association of serious AEs with LCM, the proportion of study withdrawals due to intolerable AEs at different LCM doses, and whether the tolerability profile of LCM differs according to the disorder in which it was investigated.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold>We searched MEDLINE and Cochrane CENTRAL to May 2011 for LCM RCTs. Additional studies were identified from reference lists of retrieved papers and from online clinical databases. We selected placebo\u2010controlled, double\u2010blind RCTs and investigated the therapeutic effects of oral LCM in adults with any condition. AEs were assessed for their association with LCM after identification\/exclusion of synonyms, rare AEs, and non\u2010assessable AEs. We used risk differences to evaluate the association of any (99% confidence intervals [CIs]) or serious AEs (95% CIs) with LCM and to investigate dose\u2013response relationships of identified AEs.<\/jats:p><jats:p><jats:bold>Key Findings:\u2002<\/jats:bold>Ten RCTs (three in pharmacoresistant epilepsy, four in neuropathic pain, one in migraine, one in fibromyalgia, and one in knee osteoarthritis) were included in our study. Their duration varied from 12\u201318\u2003weeks. The total number of patients included was 3,148. No serious AE was significantly associated with LCM treatment. Of 21 identified AEs, 11 (52%) were found to be significantly associated with LCM. The number of AEs significantly associated with LCM increased with increasing dose: one at 200\u2003mg\/day (dizziness); six at 400\u2003mg\/day (dizziness, vertigo, abnormal coordination, abnormal vision, nausea, and vomiting); nine at 600\u2003mg\/day (dizziness, vertigo, ataxia, balance disorder, diplopia, fatigue, nausea, vomiting, and tremor). The proportion of AE\u2010related study withdrawals also significantly increased with increasing dose. LCM AEs tended to occur more frequently in patients with drug\u2010resistant epilepsy compared with patients with other disorders.<\/jats:p><jats:p><jats:bold>Significance:\u2002<\/jats:bold>A range of AEs suggestive of vestibulocerebellar dysfunction is significantly associated with LCM treatment and their incidence increases with increasing doses.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2012.03589.x","type":"journal-article","created":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T17:15:01Z","timestamp":1341940501000},"page":"66-74","source":"Crossref","is-referenced-by-count":79,"title":["The adverse event profile of lacosamide: A systematic review and meta\u2010analysis of randomized controlled trials"],"prefix":"10.1111","volume":"54","author":[{"given":"Gaetano","family":"Zaccara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Loiacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giovannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,10]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Anon.(2009)Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee. Study NCT00485472. NIH clinical trial registry (http:\/\/www.clinicaltrial.gov)."},{"key":"e_1_2_8_3_1","unstructured":"Anon.(2010a)Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. Study NCT00401830. NIH clinical trial registry (http:\/\/www.clinicaltrial.gov)."},{"key":"e_1_2_8_4_1","unstructured":"Anon.(2010b)A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis (SP906). Study NCT00440518. NIH clinical trial registry (http:\/\/www.clinicaltrial.gov)."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02482.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01128.x"},{"key":"e_1_2_8_7_1","first-page":"63","article-title":"Adverse effects of anticonvulsant drugs \u2013 a critical review","volume":"5","author":"Beghi E","year":"1986","journal-title":"Adverse Drug React Acute Poisoning Rev"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.455003.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01188.x"},{"key":"e_1_2_8_10_1","first-page":"CD001416","article-title":"Zonisamide for drug\u2010resistant partial epilepsy","volume":"2","author":"Chadwick DW","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_11_1","first-page":"CD001416","article-title":"Zonisamide add\u2010on for drug\u2010resistant partial epilepsy","volume":"2","author":"Chadwick DW","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_12_1","first-page":"CD001416","article-title":"Zonisamide add\u2010on for drug\u2010resistant partial epilepsy","volume":"4","author":"Chadwick DW","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_13_1","first-page":"CD001901","article-title":"Levetiracetam add\u2010on for drug\u2010resistant localization related (partial) epilepsy","volume":"1","author":"Chaisewikul R","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.488639"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02496.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.04.043"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.039867"},{"key":"e_1_2_8_18_1","first-page":"342:d1555","article-title":"Network meta\u2010analysis. Results can be summarised in a simple figure","volume":"23","author":"Fadda V","year":"2011","journal-title":"BMJ"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01951.x"},{"key":"e_1_2_8_20_1","first-page":"(3)","article-title":"Vigabatrin for refractory partial epilepsy","volume":"16","author":"Hemming K","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161210791959854"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.08.032"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1980.tb04081.x"},{"key":"e_1_2_8_24_1","first-page":"CD001417","article-title":"Topiramate for drug\u2010resistant partial epilepsy","volume":"2","author":"Jette NJ","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_25_1","first-page":"CD001417","article-title":"Topiramate add\u2010on for drug\u2010resistant partial epilepsy","volume":"3","author":"Jette NJ","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_26_1","first-page":"(3)","article-title":"Topiramate add\u2010on for drug\u2010resistant partial epilepsy","volume":"16","author":"Jette N","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200822010-00003"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2162-07.2007"},{"key":"e_1_2_8_29_1","first-page":"CD001900","article-title":"Remacemide for drug\u2010resistant localization related epilepsy","volume":"4","author":"Leach JP","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1468-6708-3-6"},{"key":"e_1_2_8_31_1","first-page":"CD005612","article-title":"Pregabalin add\u2010on for drug\u2010resistant partial epilepsy","volume":"23","author":"Lozsadi D","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01251.x"},{"key":"e_1_2_8_33_1","first-page":"CD001415","article-title":"Gabapentin for drug\u2010resistant partial epilepsy","volume":"2","author":"Marson AG","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00287-X"},{"key":"e_1_2_8_35_1","first-page":"CD004154","article-title":"Clobazam as an add\u2010on in the management of refractory epilepsy","volume":"16","author":"Michael B","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03212.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.10.002"},{"key":"e_1_2_8_38_1","first-page":"CD001908","article-title":"Tiagabine add\u2010on for drug\u2010resistant partial epilepsy","volume":"3","author":"Pereira J","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000345667.45642.61"},{"key":"e_1_2_8_40_1","first-page":"CD001909","article-title":"Lamotrigine add\u2010on for drug\u2010resistant partial epilepsy","volume":"3","author":"Ramaratnam S","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000210957.39621.b2"},{"key":"e_1_2_8_42_1","volume-title":"Review Manager (RevMan) [Computer program]. Version 5.1","author":"RevMan","year":"2011"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S4716"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587550-000000000-00000"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2009.01.322"},{"key":"#cr-split#-e_1_2_8_46_1.1","unstructured":"ShukrallaAA Tudur\u2010SmithC MarsonAG. (2001)Adverse events of antiepileptic drugs across indications: can randomized controlled trials data from non\u2010epilepsy indications be included in meta\u2010analysis for AEDs used in epilepsy?Special Issue: 29th International Epilepsy Congress Rome 28th August-1st September 2011"},{"key":"#cr-split#-e_1_2_8_46_1.2","unstructured":"August 2011 Volume 52 Issue Supplement s6 Pages 1-298."},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.07.035"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1187"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318196d2b6"},{"key":"e_1_2_8_50_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1684\/j.1950-6945.2004.tb00064.x","article-title":"Adverse motor effects induced by antiepileptic drugs","volume":"6","author":"Zaccara G","year":"2004","journal-title":"Epileptic Disord"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01041.x"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02966.x"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1213-x"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1578"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2010.04.018"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2012.03589.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2012.03589.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T17:44:46Z","timestamp":1714153486000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2012.03589.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,10]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1528-1167.2012.03589.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03589.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,10]]}}}